ProKidney posts pooled Phase 2 data showing rilparencel stabilizes kidney function in advanced CKD with diabetes

Bitget2026/10/02 13:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ProKidney flagged a new pooled Phase 2 analysis in advanced CKD with type 2 diabetes, with results scheduled for presentation at ASN Kidney Week 2026.
The analysis continued to show a favorable safety profile, with signs of kidney function stabilization in patients matching key Phase 3 eligibility criteria.
The company also set an oral presentation on non-clinical data supporting a multifactorial rilparencel mechanism tied to tissue repair and reduced injury signaling.
Updates add support for the ongoing Phase 3 PROACT 1 study, a key value driver for rilparencel in chronic kidney disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838326) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ProKidney posts pooled Phase 2 data showing rilparencel stabilizes kidney function in advanced CKD with diabetes

You may also like

Crypto prices